

## Dear State Surveyor:

This report is designed to provide a comparative summary of treatment patterns and patient outcomes for End Stage Renal Disease (ESRD) patients in this state, as compared to all patients in the United States. The statistics reported here include dialysis patients treated during 2020-2023 in the chronic dialysis facilities in this state and are based primarily on data from the ESRD Quality Reporting System (EQRS), Medicare claims, and data collected for CMS. Selected statistics from this profile are summarized below and state-to-state comparisons of key statistics are provided in the *Maps and Tables of Key Statistics by State*.

## ESRD CORE Pre-Survey Data Tool

For each facility with CCN xxxxxx in your state, key data elements from the DFR reviewed in the Core Survey Pre-survey Preparation task are reported in the QDFR\_FY25\_SEP\_UPDATE\_xxxxxx.pdf available on the secure Dialysis Reports website ([www.DialysisData.org](http://www.DialysisData.org)).

Selected highlights for this State are provided on the first few pages. For a complete description of the methods and data reported here please see the *Guide to the State Profiles for FY 2025*. The Guide is available on the Dialysis Data website at [www.DialysisData.org](http://www.DialysisData.org). We hope this profile is of interest to you and is helpful in your survey efforts. We welcome your feedback on ways to improve future profiles.

## What's New This Year

As part of a continuing effort to improve the quality and relevance of this report for your state, the following changes have been incorporated into the State Profile for FY 2025: (1) The Standardized Modality Switch Ratio for incident in-center hemodialysis patients (SMoSR) was added to Table 2. This measure provides an adjusted modality outcome for patients who, in their first year of treatment, switch to a home dialysis modality (PD or HHD). Switches to home dialysis in the first year reflect that the facility is providing effective access to modality education and resources that can support patient modality decisions. (2) The percentage of prevalent patients on the waitlist in active status was added to Table 6. This measure is similar to the age-adjusted percentage of patient-months waitlisted measure, but only includes patients in active status and provides information about the facilities' ongoing support, as patients can lapse from active status. (3) Tables C1 and C2 now provide COVID-19 patient counts, deaths, and hospitalizations among Medicare dialysis patients for each year of the reporting period. (4) Table footnotes that may be referenced across multiple tables have been moved to a new Appendix following the tables at the end of the report.

## Data Limitations

The COVID Extraordinary Circumstances Exception (ECE) data policy from CMS restricts the use and availability of claims data from March-June 2020 and EQRS clinical data from January-June 2020. Table footnotes provide additional details of data availability for each measure in 2020.

## State Highlights

**Patient Characteristics:** On December 31<sup>st</sup>, 2023, 11.8% of patients in this state were treated in a nursing home during the year, compared to 13.0% nationally. See **Table 1** for detailed summaries of all patients treated during 2020-2023 in this state.

Form CMS-2728 collected data from 2,156 incident patients in this state in 2023. **Table 2** describes certain important characteristics of these patients at the time of their first outpatient dialysis session, including patients' demographics, medical coverage, primary cause of ESRD, modality, pre-treatment nephrological care, transplant options, and vascular access type. In 2023, the average age of patients in this state at incidence was 63 years, compared to the national average of 63 years. Asian patients made up 11% of the patients in this state compared to 6% nationally. Among the incident patients in this state in 2023, 90.3% were informed of their transplant options, compared to 93.0% nationally. Also in 2023, 16.9% of incident patients in this state were not under the care of a nephrologist prior to ESRD therapy, compared to 15.6% nationally.

**Mortality:** There were 1,486 deaths among the patients treated in this state during 2023, while 1,464 would be expected based on their age, race, ethnicity, sex, diabetes status, duration of ESRD, nursing home status, BMI and comorbidities at incidence, as well as state population death rates. The Standardized Mortality Ratio (SMR) of observed to expected deaths is 1.00, which is 0% higher than expected. Of the deaths in this state in 2023, 27% were preceded by withdrawal from dialysis, compared to the national average of 22%. See **Table 3** of this profile for more detailed mortality statistics during 2020-2023 in this state.

**First Year Mortality:** There were 356 deaths among the incident patients treated in this state during 2022, while 353 would be expected based on their age, race, ethnicity, sex, diabetes status, nursing home status, BMI and comorbidities at incidence, as well as state population death rates. The First Year Standardized Mortality Ratio (SMR) of observed to expected deaths is 1.02, which is 2% higher than expected. Of the deaths among incident patients in this state in 2022, 27% were preceded by withdrawal from dialysis, compared to the national average of 22%. See **Table 3** of this profile for more detailed first year mortality statistics during 2020-2022 in this state.

**Hospitalization:** The Standardized Hospitalization Ratio (SHR) of observed to expected hospital admissions for patients in this state during 2023 is 0.90, indicating that these patients had 10% fewer admissions than expected based on characteristics of patients treated in this state. The Standardized Readmission Ratio (SRR) of observed to expected hospital readmissions in this state during 2023 is 1.01, indicating that these patients had 1% more readmissions than expected. See **Table 4** of this profile for additional hospitalization statistics during 2020-2023 in this state.

**Transplantation:** 328 patients under age 75 in this state during 2023 received their first transplant, while 324 would be expected based on the age of these patients. The Standardized Transplantation Ratio (STR) of observed to expected number of patients transplanted for this state is 0.97, which is 3% lower than expected. See **Table 5** of this profile for additional transplantation statistics during 2020-2023 in this state.

**Kidney Transplant Waitlist for Prevalent Patients:** The 2023 age-adjusted percent waitlisted in this state is 14.5%, which is 1.5% lower than the national adjusted percentage. See **Table 5** of this profile for additional transplant waitlist statistics during 2020-2023 in this state.

**Kidney Transplant Waitlist for Incident Patients:** The 2022 Standardized Waitlist Ratio (SWR) in this state is 0.95, which is 5% fewer patients waitlisted or living donor transplants than expected in this state. See **Table 5** of this profile for additional transplant waitlist statistics during 2020-2022 in this state.

**Influenza Vaccination:** On December 31, 2023, 77% of all patients treated in this state were vaccinated against influenza between August 1 and December 31, 2023, compared to 78% nationally. This difference is statistically significant ( $p < 0.05$ ) and is unlikely to be due to random chance. See **Table 6** of this profile for more information about vaccinated patients during 2020-2023 in this state.

**Anemia Management:** In 2023, 22.7% of eligible hemodialysis patient-months in this state had a hemoglobin value below 10 g/dL, compared to 23.0% nationally. In 2023, 20.7% of eligible peritoneal dialysis patient-months had a hemoglobin value below 10 g/dL, compared to 22.6% nationally. See **Table 7** of this profile for additional anemia management statistics in this state during 2020-2023.

**Dialysis Adequacy:** Of the eligible hemodialysis patient-months in this state in 2023, 97% had a Kt/V  $\geq 1.2$ , compared to 97% nationally. Of the eligible peritoneal dialysis patient-months in this state in 2023, 92% had a Kt/V  $\geq 1.7$ , compared to 92% nationally. See **Table 8** of this profile for more information on dialysis during 2020-2023 in this state.

**Mineral Metabolism:** In 2023, 16% of eligible patient-months in this state had a serum phosphorus value  $>7.0$  mg/dL, compared to 16% nationally. Also in 2023, 1.1% of eligible patient-months in this state had a calcium uncorrected value  $>10.2$  mg/dL, compared to 1.0% nationally. See **Table 9** of this profile for more mineral metabolism summaries in this state during 2020-2023.

**Vascular Access:** In 2023, 13% of the incident hemodialysis patients in this state had an arteriovenous (AV) fistula in use, compared to 12% in the nation. This state's 2023 Standardized Fistula Rate (SFR) for prevalent patients is 59%, which is 0% higher than the national SFR. Of the prevalent patients receiving hemodialysis treatment in this state, the long-term catheter rate was 18%, compared to 18% nationally. See **Table 10** of this profile for additional information about vascular access in this state during 2020-2023.

SAMPLE

State Profile for FY 2025 for Dialysis Patients and Facilities  
STATE SAMPLE

The tables below provide updates of COVID-19 patient counts, deaths, and hospitalizations among Medicare dialysis patients (Table C1) and Medicare nursing home (NH) dialysis patients (Table C2), 2020-2023. National averages for 2023 are reported for comparison.

**TABLE C1. COVID among Medicare Dialysis Patients, 2020-2023**<sup>\*1</sup>

| Outcome Description   | This State |       |       |       | United States |
|---|------------|-------|-------|-------|---------------|
|   | 2020       | 2021  | 2022  | 2023  | 2023          |
| 1 Medicare dialysis patients (n)                                  | 9,679      | 9,586 | 9,258 | 9,016 | n/a           |
| 2 Patients ever infected with COVID (n)                           | 1,102      | 1,835 | 2,590 | 2,382 | n/a           |
| Patients ever infected with COVID (% of 1)                        | 10.1       | 17.7  | 27.7  | 26.1  | 26.4          |
| 3 Patients initially infected with COVID (n)                      | 1,091      | 1,013 | 1,269 | 460   | n/a           |
| Patients initially infected with COVID (% of 1)                   | 9.9        | 9.8   | 14.0  | 5.1   | 5.2           |
| <b>Deaths among Medicare patients</b>                             |            |       |       |       |               |
| 4 Deaths (n)  | 1,579      | 1,537 | 1,417 | 1,323 | n/a           |
| 5 Deaths among patients ever infected with COVID (n)              | 276        | 438   | 504   | 449   | n/a           |
| Deaths among patients ever infected with COVID (% of 4)           | 14.4       | 24.7  | 35.1  | 33.4  | 33.9          |
| <b>Hospitalizations<sup>*2</sup> among Medicare patients</b>      |            |       |       |       |               |
| 6 Hospitalizations (n)  | 5,693      | 5,593 | 5,386 | 5,184 | n/a           |
| 7 Hospitalizations among patients ever infected with COVID (n)    | 957        | 1,381 | 1,849 | 1,595 | n/a           |
| Hospitalizations among patients ever infected with COVID (% of 6) | 14.8       | 22.5  | 34.1  | 30.6  | 30.7          |

**TABLE C2. COVID among Medicare Dialysis Patients Treated in Nursing Home (NH) Facilities, 2020-2023**<sup>\*1</sup>

| Outcome Description   | This State |       |       |       | United States |
|---|------------|-------|-------|-------|---------------|
|   | 2020       | 2021  | 2022  | 2023  | 2023          |
| 1 Medicare NH dialysis patients (n)                               | 1,663      | 1,641 | 1,609 | 1,622 | n/a           |
| 2 Patients ever infected with COVID (n)                           | 429        | 540   | 672   | 606   | n/a           |
| Patients ever infected with COVID (% of 1)                        | 22.4       | 30.8  | 40.9  | 37.0  | 37.5          |
| 3 Patients initially infected with COVID (n)                      | 424        | 266   | 341   | 147   | n/a           |
| Patients initially infected with COVID (% of 1)                   | 22.0       | 15.0  | 21.6  | 9.1   | 9.2           |
| <b>Deaths among Medicare NH patients</b>                          |            |       |       |       |               |
| 4 Deaths (n)  | 554        | 490   | 470   | 467   | n/a           |
| 5 Deaths among patients ever infected with COVID (n)              | 131        | 173   | 205   | 188   | n/a           |
| Deaths among patients ever infected with COVID (% of 4)           | 19.2       | 33.1  | 45.9  | 39.6  | 40.3          |
| <b>Hospitalizations<sup>*2</sup> among Medicare NH patients</b>   |            |       |       |       |               |
| 6 Hospitalizations (n)  | 1,437      | 1,409 | 1,375 | 1,368 | n/a           |
| 7 Hospitalizations among patients ever infected with COVID (n)    | 386        | 462   | 584   | 516   | n/a           |
| Hospitalizations among patients ever infected with COVID (% of 6) | 23.6       | 31.0  | 41.8  | 37.8  | 37.7          |

[\*1] Includes patients with Medicare as primary insurer or with a Medicare Advantage plan. Table C2 includes patients who were treated in a nursing home at least one day during the year. See *Guide, Section XVII*.

[\*2] Hospitalization is defined as having at least one day in a hospital from Medicare inpatient claims during the reporting period.

State Profile for FY 2025 for Dialysis Patients and Facilities  
STATE SAMPLE

**TABLE 1: Summaries for All Dialysis Patients Treated as of December 31<sup>st</sup> of each Year<sup>\*1</sup>, 2020-2023**

| Measure Name  | 2020  | This State |       |       | United States |
|---|-------|------------|-------|-------|---------------|
|   |       | 2021       | 2022  | 2023  | 2023          |
| 1a Patients treated on 12/31 of year (n)              | 8,752 | 8,534      | 8,369 | 8,317 | 465,724       |
| 1b Average age (years)                                | 62.0  | 62.2       | 62.2  | 62.3  | 62.5          |
| 1c Age (% of 1a; sums to 100%)                        |       |            |       |       |               |
| < 18  | 0.2   | 0.2        | 0.2   | 0.2   | 0.3           |
| 18-64   | 53.0  | 52.2       | 51.7  | 51.4  | 51.0          |
| 65+   | 46.8  | 47.6       | 48.1  | 48.3  | 48.7          |
| 1d Female (% of 1a)                                   | 42.3  | 42.2       | 42.0  | 41.8  | 41.8          |
| 1e Race (% of 1a; sums to 100%)                       |       |            |       |       |               |
| African American                                      | 27.9  | 28.1       | 28.1  | 27.9  | 33.9          |
| Asian/Pacific Islander                                | 10.8  | 11.0       | 11.1  | 11.1  | 6.9           |
| Native American                                       | 3.5   | 3.6        | 3.8   | 4.3   | 2.1           |
| White   | 57.4  | 57.0       | 56.6  | 56.2  | 56.8          |
| Other/Unknown/Missing                                 | 0.4   | 0.4        | 0.4   | 0.4   | 0.3           |
| 1f Ethnicity (% of 1a; sums to 100%)                  |       |            |       |       |               |
| Hispanic  | 13.4  | 13.9       | 14.4  | 14.7  | 23.2          |
| Non-Hispanic  | 86.5  | 86.0       | 85.5  | 85.2  | 76.8          |
| Unknown   | 0.1   | 0.1        | 0.1   | 0.1   | 0.1           |
| 1g Cause of ESRD (% of 1a; sums to 100%)              |       |            |       |       |               |
| Diabetes  | 47.7  | 47.2       | 46.5  | 46.1  | 44.7          |
| Hypertension  | 26.3  | 26.4       | 26.7  | 26.9  | 30.6          |
| Glomerulonephritis                                    | 10.9  | 10.5       | 10.3  | 10.0  | 8.9           |
| Other/Unknown   | 14.8  | 15.5       | 16.1  | 16.5  | 15.3          |
| Missing   | 0.4   | 0.4        | 0.4   | 0.5   | 0.5           |
| 1h Average duration of ESRD (years)                   | 4.9   | 4.9        | 4.9   | 4.9   | 4.9           |
| 1i Years since start of ESRD (% of 1a; sums to 100%)  |       |            |       |       |               |
| <1  | 16.1  | 17.0       | 16.8  | 17.0  | 16.8          |
| 1-2   | 17.8  | 17.2       | 18.1  | 17.8  | 17.7          |
| 2-3   | 13.8  | 14.2       | 13.7  | 14.2  | 14.2          |
| 3-6   | 26.0  | 25.4       | 25.6  | 25.3  | 25.2          |
| 6+  | 26.3  | 26.2       | 25.8  | 25.7  | 26.1          |
| 1j Nursing facility patients <sup>**2</sup> (% of 1a) | 11.4  | 11.7       | 11.6  | 11.8  | 13.0          |
| 1k Modality (% of 1a; sums to 100%)                   |       |            |       |       |               |
| In-center hemodialysis                                | 85.0  | 84.4       | 83.7  | 83.1  | 83.2          |
| Home hemodialysis                                     | 2.7   | 3.0        | 3.3   | 3.7   | 3.5           |
| Continuous ambulatory peritoneal dialysis             | 1.6   | 1.5        | 1.5   | 1.6   | 1.5           |
| Continuous cycling peritoneal dialysis                | 10.2  | 10.7       | 11.0  | 11.1  | 11.5          |
| Other modality  | 0.4   | 0.5        | 0.5   | 0.4   | 0.3           |

n/a = not applicable.

[\*1] See *Guide, Section IV* for detailed information regarding the summaries included in Table 1.

[\*2] Includes patients who were treated at a nursing facility at any time during the year. The source of nursing facility history of patients is the Nursing Home Minimum Dataset.

State Profile for FY 2025 for Dialysis Patients and Facilities  
STATE SAMPLE

**TABLE 2: Characteristics of New Dialysis Patients<sup>\*1</sup>, 2020-2023 (Form CMS-2728)**

| Measure Name   | This State   |       |       |       | United States |         |
|--|--|-------|-------|-------|---------------|---------|
|  | 2020   | 2021  | 2022  | 2023  | 2023          |         |
| <b>Patient Characteristics</b>                           |  |       |       |       |               |         |
| 2a   | Total number of patients with forms (n)                          | 2,179 | 2,265 | 2,178 | 2,156         | 120,759 |
| 2b   | Age (average years [0-95]) <sup>*2</sup>                         | 62.2  | 62.5  | 62.5  | 62.7          | 62.9    |
| 2c   | Female (% of 2a)   | 41.7  | 41.5  | 41.9  | 41.3          | 41.2    |
| 2d   | Race (% of 2a; sums to 100%)                                     |       |       |       |               |         |
|  | African American   | 23.4  | 23.4  | 23.5  | 23.2          | 27.8    |
|  | Asian/Pacific Islander   | 10.3  | 10.6  | 10.5  | 10.6          | 6.2     |
|  | Native American  | 3.2   | 3.4   | 4.1   | 5.4           | 3.7     |
|  | White  | 62.8  | 62.3  | 61.3  | 60.3          | 61.8    |
|  | Other/Unknown/Missing  | 0.3   | 0.3   | 0.6   | 0.6           | 0.5     |
| 2e   | Hispanic (% of 2a)   | 12.2  | 12.9  | 13.2  | 13.0          | 20.4    |
| 2f   | Primary cause of ESRD (% of 2a; sums to 100%)                    |       |       |       |               |         |
|  | Diabetes   | 49.8  | 48.1  | 47.4  | 47.5          | 44.6    |
|  | Hypertension   | 25.4  | 26.1  | 26.7  | 27.2          | 31.1    |
|  | Glomerulonephritis   | 7.2   | 7.1   | 7.3   | 6.8           | 5.9     |
|  | Other/Missing  | 17.6  | 18.7  | 18.6  | 18.5          | 18.4    |
| 2g   | Medical Coverage (% of 2a; sums to 100%)                         |       |       |       |               |         |
|  | Employer group only  | 12.9  | 12.0  | 12.1  | 11.3          | 11.3    |
|  | Medicare only  | 32.8  | 41.2  | 42.9  | 42.9          | 44.4    |
|  | Medicaid only  | 16.6  | 17.0  | 16.0  | 16.7          | 15.3    |
|  | Medicare and Medicaid only                                       | 10.1  | 7.0   | 7.1   | 8.0           | 7.8     |
|  | Medicare and Other   | 14.3  | 9.4   | 9.5   | 10.0          | 8.3     |
|  | Other/Unknown  | 8.6   | 9.8   | 9.0   | 8.1           | 9.1     |
|  | None   | 4.7   | 3.6   | 3.4   | 3.1           | 3.8     |
| 2h   | Body Mass Index  |       |       |       |               |         |
|  | Male   | 28.4  | 28.4  | 28.1  | 27.9          | 27.7    |
|  | Female   | 29.6  | 29.4  | 28.9  | 28.9          | 28.5    |
| 2i   | Employment (% of 2a)   |       |       |       |               |         |
|  | Six months prior to ESRD treatment                               | 36.5  | 35.0  | 37.8  | 38.8          | 36.8    |
|  | At first ESRD treatment  | 26.7  | 26.1  | 29.0  | 30.5          | 27.3    |
| 2j   | Primary Modality (% of 2a; sums to 100%)                         |       |       |       |               |         |
|  | Hemodialysis   | 87.3  | 87.2  | 86.1  | 85.5          | 85.1    |
|  | CAPD/CCPD  | 12.7  | 12.8  | 13.9  | 14.5          | 14.9    |
|  | Other/Unknown/Missing  | 0.0   | 0.0   | 0.0   | 0.0           | 0.0     |
| 2k   | Number of incident hemodialysis patients (n)                     | 1,888 | 1,962 | 1,863 | 1,835         | 102,733 |
| 2l   | Access used at first outpatient dialysis (% of 2k; sums to 100%) |       |       |       |               |         |
|  | Arteriovenous fistula  | 15.3  | 13.4  | 13.8  | 14.3          | 13.1    |
|  | Arteriovenous graft  | 2.4   | 2.5   | 2.9   | 2.7           | 3.0     |
|  | Catheter   | 81.9  | 83.8  | 83.0  | 82.7          | 83.6    |
|  | Other/Unknown/Missing  | 0.3   | 0.3   | 0.3   | 0.3           | 0.3     |
| 2m   | Arteriovenous fistulae placed (% of 2k) <sup>*3</sup>            | 26.5  | 24.7  | 23.8  | 24.2          | 22.8    |
| <b>Average Lab Values Prior to Dialysis<sup>*2</sup></b> |  |       |       |       |               |         |
| 2n   | Hemoglobin (g/dL [5-20])   | 9.4   | 9.3   | 9.3   | 9.3           | 9.3     |
| 2o   | Serum Albumin (g/dL [0.8-6.0])                                   | 3.3   | 3.4   | 3.4   | 3.4           | 3.4     |
| 2p   | Serum Creatinine (mg/dL [0-33])                                  | 6.7   | 6.7   | 6.7   | 6.6           | 6.5     |
| 2q   | GFR (ml/min [0-30])  | 9.7   | 9.7   | 9.7   | 9.8           | 9.9     |

(continued)

**TABLE 2 (continued): Characteristics of New Dialysis Patients<sup>\*1</sup>, 2020-2023 (Form CMS-2728)**

| Measure Name                                      | This State   |                   |       |       | United States |         |
|---|--|-------------------|-------|-------|---------------|---------|
|   | 2020   | 2021              | 2022  | 2023  | 2023          |         |
| <b>Care Prior to ESRD Therapy</b>                 |  |                   |       |       |               |         |
| 2r  | Received ESA prior to ESRD (% of 2a)               | 16.7              | 16.9  | 17.1  | 17.2          | 16.6    |
| 2s  | Pre-ESRD nephrologist care (% of 2a; sums to 100%) |                   |       |       |               |         |
|   | No   | 18.4              | 18.3  | 17.1  | 16.9          | 15.6    |
|   | Yes, <6 months                                     | 16.0              | 16.9  | 18.0  | 18.4          | 19.0    |
|   | Yes, 6-12 months                                   | 19.1              | 19.1  | 18.4  | 18.0          | 18.6    |
|   | Yes, >12 months                                    | 34.3              | 32.6  | 32.8  | 32.6          | 29.1    |
|   | Unknown  | 12.2              | 13.1  | 13.8  | 14.1          | 17.8    |
| 2t  | Informed of transplant options (% of 2a)           | 81.2              | 88.5  | 89.7  | 90.3          | 93.0    |
| 2u  | Patients not informed of transplant options (n)    | 342               | 201   | 160   | 151           | 8,430   |
| 2v  | Reason not informed (% of 2u; may not sum to 100%) |                   |       |       |               |         |
|   | Medically unfit                                    | 18.0              | 35.8  | 39.4  | 40.7          | 38.2    |
|   | Unsuitable due to age                              | 9.6               | 0.0   | 0.0   | 0.0           | 0.0     |
|   | Psychologically unfit                              | 0.8               | 0.0   | 0.0   | 0.0           | 0.0     |
|   | Patient declined information                       | 1.0               | 7.0   | 10.0  | 9.4           | 7.1     |
|   | Patient has not been assessed                      | 64.1              | 50.9  | 54.9  | 54.9          | 53.8    |
| <b>Comorbid Conditions</b>                        |  |                   |       |       |               |         |
| 2w  | Pre-existing Comorbidity (% yes of 2a)             |                   |       |       |               |         |
|   | Congestive heart failure                           | 28.0              | 27.8  | 26.3  | 26.1          | 25.7    |
|   | Atherosclerotic heart disease                      | 13.1              | 12.7  | 11.9  | 12.3          | 10.7    |
|   | Other cardiac disorder                             | 20.0              | 20.5  | 19.8  | 20.7          | 20.7    |
|   | CVD, CVA, TIA                                      | 8.7               | 8.2   | 8.5   | 7.9           | 8.1     |
|   | Peripheral vascular disease                        | 9.8               | 9.2   | 8.2   | 8.0           | 7.5     |
|   | History of hypertension                            | 87.6              | 87.2  | 86.5  | 87.2          | 87.9    |
|   | Diabetes   | 64.8              | 64.5  | 64.1  | 64.4          | 63.7    |
|   | Diabetes on insulin                                | 43.0              | 42.4  | 40.9  | 41.8          | 40.8    |
|   | COPD   | 8.9               | 8.2   | 7.8   | 7.9           | 7.5     |
|   | Current smoker                                     | 7.5               | 7.4   | 7.3   | 7.7           | 6.6     |
|   | Cancer   | 6.7               | 6.7   | 6.5   | 6.6           | 6.6     |
|   | Alcohol dependence                                 | 2.0               | 2.0   | 2.0   | 2.0           | 1.8     |
|   | Drug dependence                                    | 1.6               | 1.7   | 1.8   | 1.9           | 1.7     |
|   | Inability to ambulate                              | 6.1               | 5.8   | 5.9   | 5.5           | 5.7     |
|   | Inability to transfer                              | 3.0               | 2.8   | 3.0   | 2.6           | 3.1     |
| 2x  | Average number of comorbid conditions              | 3.1               | 3.1   | 3.0   | 3.0           | 3.0     |
| <b>Standardized Modality Switch Ratio (SMoSR)</b> |  |                   |       |       |               |         |
|   |  | 2020 <sup>^</sup> | 2021  | 2022  |               | 2022    |
| 2y  | Eligible patients (n)                              | 2,009             | 2,102 | 2,004 |               | 112,313 |
| 2z  | Patient-years at risk (n)                          | 1,434             | 1,484 | 1,419 |               | 79,518  |
| 2aa   | Number of modality switches (n)                    | 182               | 189   | 181   |               | 10,111  |
| 2ab   | Expected number of modality switches (n)           | 185               | 188   | 178   |               | 9,993   |
| 2ac   | SMoSR (2aa/2ab) <sup>*A</sup>                      | 1.06              | 1.08  | 1.14  |               | 1.01    |

n/a= not applicable.

[^, \*A - \*C] See **Appendix: Table Footnotes** on page 21.

[\*1] See *Guide, Section V* for detailed information regarding the summaries included in Table 2.

[\*2] For continuous variables, all summaries are computed based only on responses in range indicated in brackets for the variable.

[\*3] Includes all patients with AV fistulae, regardless of whether they received their hemodialysis treatments using their fistulae.

**TABLE 3: Mortality Summary for All Dialysis Patients (2020-2023) ^ & New Dialysis Patients (2020-2022) \*1 ^**

| Measure Name   | This State |        |        |        | United States |
|--|------------|--------|--------|--------|---------------|
|  | 2020 ^     | 2021   | 2022   | 2023   |               |
| <b>All Patients: Standardized Mortality Ratio (SMR)</b>              |            |        |        |        |               |
| 3a Patients (n)  | 12,165     | 12,213 | 12,019 | 11,893 | 734,025       |
| 3b Patient years (PY) at risk (n)                                    | 5,907      | 8,672  | 8,449  | 8,385  | 481,341       |
| 3c Deaths (n)  | 1,177      | 1,732  | 1,594  | 1,486  | 88,886        |
| 3d Expected deaths (n)   | 1,205      | 1,856  | 1,642  | 1,464  | 84,378        |
| 3e Withdrawal from dialysis prior to death (% of 3c)                 | 26.3       | 24.5   | 26.7   | 26.8   | 22.5          |
| 3f Deaths due to infections (% of 3c)                                | 11.6       | 11.0   | 10.4   | 9.9    | 9.3           |
| 3g Deaths due to cardiac causes (% of 3c)                            | 43.6       | 42.1   | 42.5   | 44.1   | 44.9          |
| 3h Deaths due to liver disease (% of 3c)                             | 1.5        | 1.4    | 1.2    | 1.3    | 1.2           |
| 3i Dialysis unrelated deaths (n; excluded from SMR)                  | 7          | 9      | 10     | 9      | 540           |
| 3j SMR (3c /3d) *A, *2   | 0.96       | 0.91   | 0.97   | 1.00   | 1.05          |
| 3k P-value *B  | .          | 0.115  | .      | .      | n/a           |
| <b>New Patients: First-Year Standardized Mortality Ratio (FySMR)</b> |            |        |        |        |               |
| 3l Patients (n)  | 2,179      | 2,265  | 2,178  |        | 121,970       |
| 3m Patient years (PY) at risk (n)                                    | 1,219      | 1,259  | 1,226  |        | 68,650        |
| 3n Deaths (n)  | 338        | 402    | 356    |        | 19,947        |
| 3o Expected deaths (n)   | 340        | 402    | 353    |        | 19,765        |
| 3p Withdrawal from dialysis prior to death (% of 3n)                 | 25.5       | 26.7   | 27.0   |        | 22.3          |
| 3q Deaths due to infections (% of 3n)                                | 10.1       | 10.9   | 9.8    |        | 8.9           |
| 3r Deaths due to cardiac causes (% of 3n)                            | 37.6       | 38.8   | 38.6   |        | 40.2          |
| 3s Deaths due to liver disease (% of 3n)                             | 2.6        | 2.3    | 2.7    |        | 2.3           |
| 3t FySMR (3n /3o) *A, *2   | 0.96       | 1.03   | 1.02   |        | 1.00          |
| 3u P-value *B  | .          | .      | .      |        | n/a           |

n/a = not applicable.

[^, \*A - \*C] See **Appendix: Table Footnotes** on page 21.

[\*1] See *Guide, Section VI* for detailed information regarding the summaries included in Table 3.

[\*2] The SMRs (3j, 3t) are not shown if there are fewer than 3 expected deaths (3d,3o).

**TABLE 4: Hospitalization Summary for Medicare Dialysis Patients<sup>\*1</sup>, 2020-2023<sup>^</sup>**

| Measure Name   | This State        |        |        |        | United States |
|--|-------------------|--------|--------|--------|---------------|
|  | 2020 <sup>^</sup> | 2021   | 2022   | 2023   | 2023          |
| <b>Medicare Dialysis Patients</b>  |                   |        |        |        |               |
| 4a Medicare dialysis patients (n)  | 9,797             | 9,819  | 9,555  | 9,344  | 571,711       |
| 4b Patient years (PY) at risk (n)  | 4,670             | 6,815  | 6,567  | 6,384  | 363,732       |
| <b>Standardized Hospitalization Ratio (SHR) for Days Hospitalized<sup>*2</sup></b>               |                   |        |        |        |               |
| 4c Total days hospitalized (n)   | 53,046            | 75,897 | 75,592 | 71,822 | 4,345,040     |
| 4d Expected days hospitalized (n)  | 55,792            | 79,788 | 79,316 | 74,865 | 4,298,181     |
| 4e SHR for Days (4c/4d) <sup>*A</sup>  | 0.89              | 0.90   | 0.89   | 0.89   | 1.01          |
| 4f P-value for SHR (Days) <sup>*B</sup>  | 0.064             | 0.084  | 0.060  | 0.063  | n/a           |
| <b>Standardized Hospitalization Ratio (SHR) for Hospital Admissions<sup>*2, *3</sup></b>         |                   |        |        |        |               |
| 4g Total admissions (n)  | 6,665             | 9,269  | 8,807  | 9,008  | 526,499       |
| 4h Expected total admissions (n)   | 6,744             | 9,402  | 8,969  | 9,183  | 526,581       |
| 4i SHR for Admissions (4g/4h) <sup>*A</sup>  | 0.93              | 0.93   | 0.90   | 0.90   | 0.99          |
| 4j P-value for SHR (Admissions) <sup>*B</sup>  | 0.111             | 0.099  | 0.109  | 0.121  | n/a           |
| 4k Patients with septicemia (% of 4a)  | 12.5              | 11.7   | 11.8   | 11.6   | 12.1          |
| 4l One day admissions (% of 4g)  | 9.2               | 8.9    | 8.5    | 8.7    | 8.1           |
| 4m Average length of stay (days per admission)   | 7.6               | 7.8    | 8.1    | 7.8    | 8.1           |
| 4n Admissions that originate in the ED (% of 4g)   | 79.0              | 81.9   | 82.8   | 83.2   | 85.8          |
| <b>Standardized Emergency Department Encounter Ratio (SEDR)<sup>*2</sup></b>                     |                   |        |        |        |               |
| 4o Emergency department (ED) events (n)  | 4,698             | 5,426  | 4,643  | 3,919  | 225,643       |
| 4p Expected number of emergency department events (n)  | 4,742             | 5,469  | 4,711  | 3,989  | 227,332       |
| 4q SEDR (4o/4p) <sup>*A</sup>  | 1.08              | 1.09   | 1.07   | 1.03   | 0.99          |
| 4r P-value for SEDR <sup>*B</sup>  | 0.112             | 0.096  | 0.084  | 0.128  | n/a           |
| <b>Standardized Ratio of ED Encounters Occurring within 30 Days of Hospital Discharge (ED30)</b> |                   |        |        |        |               |
| 4s Index discharges (n)  | 3,480             | 4,676  | 4,014  | 3,562  | 199,462       |
| 4t Total ED visits within 30 days of hospital discharge (n)                                      | 543               | 712    | 591    | 514    | 28,770        |
| 4u Expected total ED visits within 30 days of hospital discharge (n)                             | 494               | 666    | 548    | 466    | 26,097        |
| 4v ED30 Ratio (4t/4u) <sup>*A</sup>  | 1.32              | 1.19   | 1.20   | 1.24   | 1.10          |
| <b>Standardized Readmission Ratio (SRR)<sup>*2</sup></b>   |                   |        |        |        |               |
| 4x Index discharges (n)  | 5,275             | 8,548  | 8,262  | 8,225  | 460,580       |
| 4y Total readmissions (n)  | 1,417             | 2,240  | 2,148  | 2,176  | 121,838       |
| 4z Expected total readmissions (n)   | 1,355             | 2,164  | 2,065  | 2,089  | 116,959       |
| 4aa SRR (4y/4z) <sup>*A</sup>  | 1.03              | 0.99   | 1.00   | 1.01   | 1.04          |

n/a = not applicable.

[<sup>^</sup>, \*A - \*C] See **Appendix: Table Footnotes** on page 21.

[\*1] See *Guide, Section VII* for detailed information regarding the summaries included in Table 4. SEDR and ED30 statistics include only patients with Medicare as primary insurer and exclude patients with Medicare Advantage plans. All other summaries include patients with Medicare as primary insurer or with a Medicare Advantage plan.

[\*2] SHRs and SEDR are not shown if there are less than five patient years at risk. SRR and ED30 ratios are not shown if fewer than 11 index discharges in the year.

[\*3] Rows 4g-4j exclude index COVID hospitalizations, while rows 4l-4n include all admissions. Row 4k includes diagnoses in any position on a hospital inpatient claim.

**TABLE 5: Transplantation and Waitlist Summary for All Dialysis Patients (2020-2023) ^ & New Dialysis Patients (2020-2022) ^ under Age 75 \*1**

| Measure Name   | This State   |               |             |             | United States |             |
|--|--|---------------|-------------|-------------|---------------|-------------|
|  | 2020 ^   | 2021          | 2022        | 2023        |               |             |
| <b>Transplantation: All Transplants</b>                            |  |               |             |             | <b>2023</b>   |             |
| 5a   | Eligible patients (n)  | 9,742         | 9,772       | 9,552       | 9,370         | 579,438     |
| 5b   | Transplants (n)  | 228           | 349         | 353         | 369           | 20,811      |
| <b>Transplantation: First Transplants</b>                          |  |               |             |             |               |             |
| 5c   | Eligible patients (n)  | 9,095         | 9,137       | 8,927       | 8,754         | 538,578     |
| 5d   | Patient years (PY) at risk (n)                               | 4,409         | 6,508       | 6,285       | 6,173         | 354,513     |
| 5e   | Actual 1st transplants (n)                                   | 204           | 312         | 318         | 328           | 18,526      |
| 5f   | Expected 1st transplants (n)                                 | 201           | 306         | 312         | 324           | 18,586      |
| 5g   | Standardized Transplantation Ratio (STR; 5e/5f)              | 0.97          | 0.99        | 0.99        | 0.97          | 0.99        |
| 5h   | P-value *B   | .             | .           | .           | .             | n/a         |
| <b>Dialysis Patients on the Waitlist</b>                           |  |               |             |             |               |             |
| 5i   | Eligible patients (n)  | 9,444         | 9,645       | 9,391       | 9,164         | 513,201     |
| 5j   | Patient-months at risk (n) *3                                | 55,451        | 81,834      | 78,949      | 77,614        | 4,346,396   |
| 5k   | Patient-months on the waitlist (% of 5j) *3                  | 15.4          | 15.3        | 15.2        | 14.9          | 16.5        |
| 5l   | Patient-months on the waitlist by subgroup (%) *C, *2        |               |             |             |               |             |
|  | Age < 40   | 24.2          | 23.6        | 23.4        | 23.0          | 25.1        |
|  | Age 40-74  | 14.4          | 14.3        | 14.2        | 13.9          | 15.5        |
|  | Male   | 16.4          | 16.2        | 16.2        | 15.8          | 17.7        |
|  | Female   | 14.0          | 13.8        | 13.7        | 13.4          | 14.9        |
|  | African American   | 15.5          | 15.6        | 16.1        | 15.2          | 15.7        |
|  | Asian/Pacific Islander                                       | 21.9          | 22.5        | 22.6        | 21.6          | 24.3        |
|  | Native American  | 14.9          | 14.5        | 13.0        | 11.9          | 11.6        |
|  | White, Hispanic  | 16.1          | 15.6        | 15.5        | 16.3          | 16.5        |
|  | White, Non-Hispanic  | 16.2          | 16.0        | 15.5        | 15.6          | 16.2        |
|  | Other/Unknown race   | 14.8          | 13.9        | 13.5        | 13.3          | 15.6        |
|  | Diabetes   | 12.3          | 12.1        | 12.4        | 12.4          | 14.0        |
|  | Non-diabetes   | 18.2          | 18.0        | 17.5        | 16.9          | 18.6        |
|  | Previous kidney transplant                                   | 27.8          | 27.0        | 26.9        | 25.6          | 28.0        |
|  | No previous kidney transplant                                | 14.5          | 14.4        | 14.3        | 14.1          | 15.7        |
|  | <2 years since start of ESRD                                 | 12.8          | 12.7        | 12.8        | 12.9          | 13.3        |
|  | 2-4 years since start of ESRD                                | 19.3          | 19.3        | 19.3        | 19.1          | 21.3        |
|  | 5+ years since start of ESRD                                 | 14.5          | 14.4        | 14.0        | 13.1          | 15.8        |
| 5m   | Age-adjusted percentage of patient-months waitlisted         | 15.1          | 15.0        | 14.8        | 14.5          | 16.0        |
| 5n   | Patient-months on the waitlist in active status (% of 5j) *C | 9.5           | 9.0         | 8.5         | 8.4           | 9.7         |
| 5o   | Age-adjusted % of patient-months waitlisted in active status | 9.2           | 8.8         | 8.2         | 8.2           | 9.4         |
| <b>New Dialysis Patients: Standardized Waitlist Ratio (SWR) *3</b> |  | <b>2020 ^</b> | <b>2021</b> | <b>2022</b> |               | <b>2022</b> |
| 5p   | Eligible Patients (n)  | 1,463         | 1,523       | 1,452       |               | 81,315      |
| 5q   | Patient-years at risk (n)                                    | 1,158         | 1,357       | 1,303       |               | 72,949      |
| 5r   | First waitlist events (n) *3                                 | 116           | 131         | 130         |               | 7,258       |
| 5s   | Expected 1st waitlist events (n) *3                          | 108           | 131         | 137         |               | 7,697       |
| 5t   | SWR (5r/5s) *A, *3   | 1.12          | 1.05        | 0.95        |               | 0.94        |
| 5u   | P-value for SWR *B   | 0.139         | 0.110       | .           |               | n/a         |

n/a = not applicable.

[^, \*A - \*C] See **Appendix: Table Footnotes** on page 21.

[\*1] See *Guide Section VIII* for detailed information regarding the transplant and waitlist summaries included in Table 5. Eligible patient-months (5j) include patients assigned to the facility on the last day of each month.

[\*2] The waitlist percentage for each subgroup is calculated as a rate of waitlisted patient-months to patient-months at risk in each subgroup. A missing value indicates that there were no eligible patients in the subgroup.

[\*3] An event is defined as a waitlisting or living-donor transplant. SWR is not shown if a facility has less than 2 expected waitlisted events or less than 11 eligible patients.

**TABLE 6: Influenza Vaccination Summary All Dialysis Patients<sup>\*1</sup>, Flu Seasons during August 2020-December 2023**

| Measure Name  | 2020  | This State |       |       | United States |
|---|-------|------------|-------|-------|---------------|
|   |       | 2021       | 2022  | 2023  | 2023          |
| 6a Eligible patients on 12/31 (n)                                       | 9,258 | 9,052      | 8,885 | 8,818 | 493,793       |
| 6b Patients excluded due to medical contraindication (n)                | 93    | 99         | 218   | 154   | 8,631         |
| <b>Full Flu Season (Aug. 1-Mar. 31 of following year)</b>               |       |            |       |       | <b>2022</b>   |
| 6c Patients vaccinated (% of 6a)  | 86.3  | 83.3       | 81.6  |       | 81.7          |
| 6d P-value <sup>*2</sup> (for 6c compared to U.S. value <sup>*3</sup> ) | 0.045 | 0.053      | 0.053 |       | n/a           |
| 6e Reason for no vaccination (% of 6a)                                  |       |            |       |       |               |
| Declined vaccination  | 6.5   | 7.8        | 7.9   |       | 8.3           |
| Other reason or vaccine data not available                              | 7.3   | 8.9        | 10.5  |       | 10.0          |
| <b>Half Flu Season (Aug. 1-Dec. 31)</b>                                 |       |            |       |       | <b>2023</b>   |
| 6f Patients vaccinated (% of 6a)  | 84.7  | 81.0       | 79.4  | 76.9  | 77.7          |
| 6g P-value <sup>*2</sup> (for 6f compared to U.S. value <sup>*4</sup> ) | 0.037 | 0.034      | 0.055 | 0.022 | n/a           |
| 6h Patients vaccinated by subgroup (%) <sup>*5</sup>                    |       |            |       |       |               |
| Medicare  | 85.4  | 82.1       | 80.4  | 78.1  | 79.0          |
| Medicare Advantage  | 85.9  | 84.0       | 81.0  | 78.7  | 80.0          |
| Medicare as primary insurer   | 85.3  | 81.5       | 79.8  | 77.4  | 78.1          |
| Non-Medicare  | 80.2  | 74.6       | 73.0  | 70.1  | 71.6          |
| Dual Medicare/Medicaid eligible   | 83.8  | 80.2       | 79.0  | 76.9  | 77.4          |
| Age < 18  | 75.7  | 73.8       | 64.9  | 58.5  | 59.8          |
| Age 18-39   | 78.6  | 71.6       | 70.6  | 67.5  | 67.0          |
| Age 40-64   | 83.7  | 79.4       | 77.3  | 74.2  | 74.8          |
| Age 65-74   | 85.7  | 83.1       | 81.4  | 79.4  | 80.4          |
| Age 75+   | 87.5  | 85.3       | 83.8  | 81.8  | 83.5          |
| Male  | 84.6  | 80.7       | 78.9  | 76.1  | 76.9          |
| Female  | 84.8  | 81.6       | 79.9  | 77.8  | 78.6          |
| African American  | 83.0  | 79.9       | 78.5  | 74.0  | 73.3          |
| Asian/Pacific Islander  | 89.6  | 84.8       | 83.9  | 82.0  | 82.9          |
| Native American   | 87.7  | 81.4       | 78.2  | 72.5  | 78.4          |
| White   | 87.9  | 83.6       | 80.4  | 77.7  | 79.5          |
| Other/unknown race  | 51.9  | 54.9       | 50.7  | 64.4  | 68.5          |
| Hispanic  | 87.5  | 82.3       | 82.9  | 78.5  | 81.6          |
| < 1 year since start of ESRD  | 80.1  | 74.6       | 72.1  | 69.4  | 69.9          |
| 1-2 years since start of ESRD   | 85.4  | 81.7       | 79.4  | 76.3  | 76.7          |
| 3+ years since start of ESRD  | 86.2  | 83.4       | 82.6  | 80.4  | 81.5          |

n/a = not applicable

[\*1] See *Guide, Section X* for detailed information regarding the summaries included in Table 6. All Dialysis Patients are those treated on December 31<sup>st</sup> of the reporting year.

[\*2] A p-value greater than or equal to 0.05 indicates that the difference between percent of patients vaccinated at the state and national percentage is plausibly due to random chance.

[\*3] Compared to the U.S. value for that year and time period (08/01-03/31): 87% (2020), 83% (2021), 82% (2022).

[\*4] Compared to the U.S. value for that year and time period (08/01-12/31): 86% (2020), 82% (2021), 81% (2022), 78% (2023).

[\*5] A missing value indicates that there were no eligible patients in the subgroup.

**TABLE 7: Anemia Management Summaries for Adult Dialysis Patients <sup>\*1</sup>, 2020-2023 <sup>^</sup>**

| Measure Name  | 2020 <sup>^</sup>                             | This State        |        |        | United States |           |
|---|---|-------------------|--------|--------|---------------|-----------|
|   |   | 2021              | 2022   | 2023   | 2023          |           |
| <b>Hemoglobin and ESA for Adult Hemodialysis (HD) Patients</b>        |   |                   |        |        |               |           |
| 7a  | Eligible HD patients (n)                      | 8,537             | 9,484  | 9,238  | 9,121         | 503,111   |
| 7b  | Eligible HD patient-months (n) <sup>*C</sup>  | 45,024            | 87,767 | 85,015 | 84,210        | 4,715,756 |
| 7c  | Average hemoglobin (g/dL) (average of 7b)     | 10.8              | 10.7   | 10.7   | 10.7          | 10.7      |
| 7d  | Hemoglobin categories (% of 7b; sums to 100%) |                   |        |        |               |           |
|   | <10 g/dL                                      | 21.7              | 22.3   | 23.0   | 22.7          | 23.0      |
|   | 10-<11 g/dL                                   | 33.3              | 33.5   | 33.2   | 32.3          | 32.9      |
|   | 11-12 g/dL                                    | 28.4              | 27.8   | 27.5   | 28.6          | 29.4      |
|   | >12 g/dL                                      | 13.5              | 12.5   | 12.2   | 12.8          | 12.5      |
|   | Missing/Out of range                          | 3.1               | 4.0    | 4.2    | 3.6           | 2.2       |
| 7e  | ESA prescribed (% of 7b)                      | 73.0              | 73.1   | 73.1   | 73.6          | 76.2      |
| <b>Hemoglobin and ESA for Adult Peritoneal Dialysis (PD) Patients</b> |   |                   |        |        |               |           |
| 7f  | Eligible PD patients (n)                      | 1,211             | 1,493  | 1,495  | 1,509         | 83,413    |
| 7g  | Eligible PD patient-months (n) <sup>*C</sup>  | 5,878             | 11,925 | 11,939 | 12,095        | 677,331   |
| 7h  | Average hemoglobin (g/dL) (average of 7g)     | 11.0              | 11.0   | 11.0   | 11.1          | 11.0      |
| 7i  | Hemoglobin categories (% of 7g; sums to 100%) |                   |        |        |               |           |
|   | <10 g/dL                                      | 21.0              | 20.6   | 20.9   | 20.7          | 22.6      |
|   | 10-<11 g/dL                                   | 27.5              | 27.2   | 27.1   | 26.3          | 27.5      |
|   | 11-12 g/dL                                    | 26.1              | 25.9   | 25.7   | 26.5          | 26.5      |
|   | >12 g/dL                                      | 19.9              | 20.6   | 20.6   | 21.7          | 20.2      |
|   | Missing/Out of range                          | 5.5               | 5.7    | 5.6    | 4.8           | 3.2       |
| 7j  | ESA prescribed (% of 7g)                      | 53.7              | 52.5   | 52.0   | 51.9          | 54.4      |
| <b>Standardized Transfusion Ratio (STrR)</b>                          |   |                   |        |        |               |           |
|   |   | 2020 <sup>^</sup> | 2021   | 2022   | 2023          | 2023      |
| 7k  | Adult Medicare patients (n)                   | 5,984             | 5,065  | 4,354  | 3,848         | 230,428   |
| 7l  | Patient years at risk (n)                     | 2,607             | 3,039  | 2,575  | 2,194         | 124,317   |
| 7m  | Total transfusions (n)                        | 865               | 1,025  | 816    | 688           | 40,831    |
| 7n  | Expected total transfusions (n)               | 891               | 1,060  | 855    | 719           | 40,884    |
| 7o  | STrR(7m/7n) <sup>*A, *1</sup>                 | 0.92              | 0.93   | 0.91   | 0.92          | 0.99      |
| 7p  | P-value <sup>*B</sup>                         | 0.131             | 0.120  | 0.147  | 0.148         | n/a       |

n/a = not applicable.

[<sup>^</sup>, <sup>\*A</sup> - <sup>\*C</sup>] See **Appendix: Table Footnotes** on page 21.

[\*1] See *Guide, Section XI* for detailed information regarding the summaries included in Table 7. Transfusion summaries include adult Medicare dialysis patients only and not shown if there are fewer than 10 patient-years at risk (7o).

**TABLE 8: Dialysis Adequacy Summaries for All Dialysis Patients <sup>\*1</sup>, 2020-2023 <sup>^</sup>**

| Measure Name                                   | This State   |        |        |        | United States |           |
|--|--|--------|--------|--------|---------------|-----------|
|  | 2020 <sup>^</sup>  | 2021   | 2022   | 2023   | 2023          |           |
| <b>Adult Hemodialysis (HD) Adequacy</b>        |  |        |        |        |               |           |
| 8a   | Eligible HD patients (n)                                     | 8,537  | 9,484  | 9,238  | 9,121         | 503,111   |
| 8b   | Eligible HD patient-months (n) <sup>*C</sup>                 | 45,024 | 87,767 | 85,015 | 84,210        | 4,715,756 |
| 8c   | Average serum albumin (g/dL) (average of 8b)                 | 3.9    | 3.9    | 3.9    | 3.9           | 3.9       |
| 8d   | Serum albumin categories (% of 8b; sums to 100%)             |        |        |        |               |           |
|  | < 3.0 g/dL   | 2.5    | 2.3    | 2.0    | 1.8           | 1.7       |
|  | 3.0-<3.5 g/dL  | 10.3   | 9.4    | 8.5    | 8.1           | 7.9       |
|  | 3.5-<4.0 g/dL  | 42.7   | 39.1   | 38.5   | 40.1          | 39.6      |
|  | >=4.0 g/dL   | 41.9   | 45.9   | 47.2   | 47.0          | 47.6      |
|  | Missing  | 2.7    | 3.4    | 3.9    | 3.0           | 3.1       |
| 8e   | Ultrafiltration rate average (ml/kg/hr) (average of 8b)      | 7.7    | 7.7    | 7.7    | 7.7           | 7.7       |
| 8f   | Ultrafiltration rate categories (% of 8b; sums to 100%)      |        |        |        |               |           |
|  | <=13 (ml/kg/hr)  | 86.0   | 86.5   | 86.0   | 86.3          | 86.3      |
|  | >13 (ml/kg/hr)   | 7.9    | 7.6    | 7.7    | 7.7           | 7.8       |
|  | Out of Range (>=20 ml/kg/hr)                                 | 2.4    | 2.3    | 2.4    | 2.5           | 2.4       |
|  | Missing  | 3.7    | 3.6    | 3.9    | 3.5           | 3.5       |
| 8g   | Eligible HD Kt/V patients (n) <sup>*2</sup>                  | 8,066  | 8,997  | 8,754  | 8,605         | 474,859   |
| 8h   | Eligible HD Kt/V patient-months (n) <sup>*C, *2</sup>        | 42,149 | 81,922 | 79,239 | 78,187        | 4,378,458 |
| 8i   | Average Kt/V (average of 8h) <sup>*2</sup>                   | 1.6    | 1.6    | 1.6    | 1.6           | 1.6       |
| 8j   | Kt/V categories (% of 8h; sums to 100%) <sup>*2</sup>        |        |        |        |               |           |
|  | <1.2   | 1.7    | 1.8    | 1.9    | 1.6           | 1.5       |
|  | 1.2-<1.8   | 70.8   | 71.2   | 71.6   | 69.8          | 69.9      |
|  | >=1.8  | 26.1   | 25.3   | 24.6   | 27.1          | 27.0      |
|  | Missing/Out of range   | 1.3    | 1.7    | 1.9    | 1.5           | 1.6       |
| <b>Adult Peritoneal Dialysis (PD) Adequacy</b> |  |        |        |        |               |           |
| 8k   | Eligible PD patients (n)                                     | 1,211  | 1,493  | 1,495  | 1,509         | 83,413    |
| 8l   | Eligible PD patient-months (n) <sup>*C</sup>                 | 5,878  | 11,925 | 11,939 | 12,095        | 677,331   |
| 8m   | Average Weekly Kt/V (average of 8l) <sup>*2</sup>            | 2.2    | 2.2    | 2.2    | 2.2           | 2.2       |
| 8n   | Weekly Kt/V categories (% of 8l; sums to 100%) <sup>*2</sup> |        |        |        |               |           |
|  | <1.7   | 5.0    | 4.8    | 5.1    | 4.9           | 5.0       |
|  | 1.7-<2.5   | 68.7   | 67.9   | 68.5   | 67.8          | 67.5      |
|  | >=2.5  | 22.9   | 23.6   | 23.2   | 24.4          | 24.1      |
|  | Missing/Out of range   | 3.4    | 3.7    | 3.1    | 2.9           | 3.4       |
| 8o   | Average serum albumin (g/dL) (average of 8l)                 | 3.6    | 3.7    | 3.7    | 3.7           | 3.7       |
| 8p   | Serum Albumin Categories (% of 8l; sums to 100%)             |        |        |        |               |           |
|  | < 3.0 g/dL   | 7.5    | 6.7    | 6.0    | 5.3           | 4.9       |
|  | 3.0-<3.5 g/dL  | 24.7   | 22.3   | 21.0   | 20.2          | 20.2      |
|  | 3.5-<4.0 g/dL  | 42.5   | 41.3   | 42.5   | 44.6          | 44.4      |
|  | >=4.0 g/dL   | 21.3   | 25.7   | 26.6   | 26.7          | 27.2      |
|  | Missing  | 4.0    | 4.1    | 3.9    | 3.1           | 3.3       |

(continued)

**TABLE 8 (continued): Dialysis Adequacy Summaries for All Dialysis Patients <sup>\*1</sup>, 2020-2023<sup>^</sup>**

| Measure Name  | This State        |      |      |      | United States |
|---|-------------------|------|------|------|---------------|
|   | 2020 <sup>^</sup> | 2021 | 2022 | 2023 | 2023          |
| <b>Pediatric Kt/V <sup>*2</sup></b>                       |                   |      |      |      |               |
| 8q Eligible Pediatric HD patients (n)                     | 13                | 15   | 16   | 17   | 778           |
| 8r Eligible Pediatric HD patient-months (n) <sup>*C</sup> | 59                | 96   | 108  | 113  | 5,315         |
| 8s Average Kt/V (average of 8r)                           | 1.7               | 1.8  | 1.8  | 1.7  | 1.7           |
| 8t Kt/V categories (% of 8r; sums to 100%)                |                   |      |      |      |               |
| <1.2  | 2.8               | 1.7  | 2.5  | 2.1  | 3.0           |
| 1.2-<1.8  | 58.1              | 57.1 | 51.7 | 55.2 | 58.6          |
| >= 1.8  | 34.2              | 36.5 | 38.3 | 30.9 | 28.5          |
| Missing/Out of Range                                      | 4.9               | 4.7  | 7.5  | 11.8 | 10.0          |
| 8u Eligible Pediatric PD Patients (n)                     | 18                | 21   | 20   | 19   | 920           |
| 8v Eligible Pediatric PD patient-months (n) <sup>*C</sup> | 83                | 151  | 150  | 146  | 7,001         |
| 8w Average Weekly Kt/V (average of 8v)                    | 2.4               | 2.4  | 2.4  | 2.4  | 2.4           |
| 8x Weekly Kt/V categories (% of 8v; sums to 100%)         |                   |      |      |      |               |
| <1.7  | 13.9              | 12.4 | 13.7 | 13.3 | 12.9          |
| 1.7-<2.5  | 51.1              | 49.9 | 45.3 | 45.7 | 46.5          |
| >=2.5   | 25.5              | 30.2 | 27.4 | 30.8 | 31.0          |
| Missing/Out of Range                                      | 9.5               | 7.4  | 13.5 | 10.2 | 9.7           |

n/a = not applicable.

[<sup>^</sup>, \*A - \*C] See **Appendix: Table Footnotes** on page 21.

[\*1] See *Guide, Section XII* for detailed information regarding the summaries included in Table 8.

[\*2] Kt/V summaries are supplemented with Medicare claims if missing in EQRS. HD Kt/V summaries are restricted to patients who dialyze thrice weekly. See section of Guide titled "*Determination of Thrice Weekly Dialysis*" for more information. The most recent value over a 4-month period is selected for PD Kt/V. PD Kt/V values for 2020 were calculated for quarter 4 only due to data exceptions. As a result, there are fewer eligible PD patients than what is reported (8u-v) for Kt/V summaries since the 3-month lookback window includes data covered by CMS' COVID-19 ECE policy.

**TABLE 9: Mineral Metabolism Summaries for All Adult Dialysis Patients <sup>\*1</sup>, 2020-2023 <sup>^</sup>**

| Measure Name   | This State        |        |        |        | United States |
|--|-------------------|--------|--------|--------|---------------|
|  | 2020 <sup>^</sup> | 2021   | 2022   | 2023   | 2023          |
| 9a Eligible adult patients (n)                                 | 9,628             | 10,684 | 10,444 | 10,340 | 569,949       |
| 9b Eligible adult patient-months (n) <sup>*C</sup>             | 51,025            | 99,948 | 97,210 | 96,547 | 5,406,606     |
| 9c Average Phosphorus (mg/dL) <sup>*2</sup>                    | 5.5               | 5.5    | 5.5    | 5.5    | 5.5           |
| 9d Phosphorus categories (% of 9b; sums to 100%) <sup>*2</sup> |                   |        |        |        |               |
| <3.5 mg/dL   | 7.2               | 6.7    | 7.4    | 7.2    | 7.4           |
| 3.5-4.5 mg/dL  | 22.4              | 21.6   | 22.1   | 21.8   | 22.3          |
| 4.6-5.5 mg/dL  | 28.5              | 28.0   | 27.2   | 26.6   | 27.4          |
| 5.6-7.0 mg/dL  | 22.7              | 22.9   | 22.5   | 23.7   | 23.7          |
| >7.0 mg/dL   | 15.3              | 15.9   | 15.7   | 16.3   | 16.3          |
| Out of Range (<0.01 mg/dL or >20 mg/dL)                        | 0.0               | 0.0    | 0.0    | 0.0    | 0.0           |
| Missing  | 4.0               | 4.8    | 5.0    | 4.3    | 2.9           |
| 9e Average Calcium Uncorrected (mg/dL)                         | 8.9               | 8.9    | 8.9    | 8.9    | 8.8           |
| 9f Calcium Uncorrected categories (% of 9b; sums to 100%)      |                   |        |        |        |               |
| <8.4 mg/dL   | 20.1              | 18.5   | 18.6   | 19.9   | 20.3          |
| 8.4-10.2 mg/dL   | 75.7              | 76.6   | 76.3   | 75.8   | 76.1          |
| >10.2 mg/dL  | 1.2               | 1.3    | 1.2    | 1.1    | 1.0           |
| Out of Range (<0.01 mg/dL or >20 mg/dL)                        | 0.0               | 0.0    | 0.0    | 0.0    | 0.0           |
| Missing  | 2.9               | 3.6    | 3.8    | 3.2    | 2.7           |
| 9g Average uncorrected calcium > 10.2 mg/dL (%) <sup>*3</sup>  | 2.4               | 2.9    | 2.7    | 2.4    | 1.9           |

n/a = not applicable.

[<sup>^</sup>, \*A - \*C] See **Appendix: Table Footnotes** on page 21.

[\*1] See *Guide, Section XIII* for detailed information regarding the summaries included in Table 9.

[\*2] Eligible patients included in the phosphorous summaries differ slightly from what is reported in 9b since it includes patient-months within the first 90 days of ESRD.

[\*3] Hypercalcemia is averaged from uncorrected serum or plasma calcium values over a rolling 3-month period. Eligible patients included in the hypercalcemia summary differs slightly from what is reported in 9b since patients must be 18 as of the first day of the 3-month period.

**TABLE 10: Vascular Access Information for all Adult Dialysis Patients and Access-Related Infection Summaries for all Medicare Patients<sup>\*1</sup>, 2020-2023<sup>^</sup>**

| Measure Name                               | This State   |                   |        |        | United States |           |
|--|--|-------------------|--------|--------|---------------|-----------|
|  | 2020 <sup>^</sup>  | 2021              | 2022   | 2023   | 2023          |           |
| <b>Vascular Access<sup>*2</sup></b>        |  |                   |        |        |               |           |
| 10a  | Prevalent adult hemodialysis (HD) patients (n)                       | 8,941             | 9,997  | 9,726  | 9,558         | 527,191   |
| 10b  | Prevalent adult hemodialysis patient months (n) <sup>*C</sup>        | 46,771            | 91,537 | 88,600 | 87,242        | 4,885,526 |
| 10c  | Vascular access type in use (% of 10b; sums to 100%)                 |                   |        |        |               |           |
|  | Arteriovenous fistula  | 62.5              | 61.2   | 59.9   | 59.3          | 58.7      |
|  | Arteriovenous graft  | 15.8              | 15.6   | 15.3   | 15.2          | 16.3      |
|  | Catheter   | 19.8              | 20.5   | 21.9   | 23.2          | 23.0      |
|  | Other/Missing  | 2.0               | 2.7    | 2.8    | 2.3           | 2.0       |
| 10d  | Standardized Fistula Rate (SFR) <sup>*3</sup>                        | 62.5              | 60.5   | 59.0   | 58.6          | 58.3      |
| 10e  | Long-Term Catheter Rate <sup>*4</sup>                                | 15.1              | 16.1   | 17.4   | 18.2          | 17.9      |
| <b>Vascular Access at First Treatment</b>  |  |                   |        |        |               |           |
| 10f  | Incident adult hemodialysis patients (n)                             | 1,022             | 1,979  | 1,880  | 1,865         | 104,458   |
| 10g  | Vascular access type in use (% of 10f; sums to 100%)                 |                   |        |        |               |           |
|  | Arteriovenous fistula  | 14.0              | 13.2   | 13.1   | 13.4          | 12.5      |
|  | Arteriovenous graft  | 2.8               | 2.8    | 3.0    | 3.1           | 3.3       |
|  | Catheter   | 81.1              | 82.4   | 81.5   | 79.1          | 80.2      |
|  | Other/Missing  | 2.1               | 1.6    | 2.3    | 4.5           | 4.0       |
| 10h  | Arteriovenous fistulae in placed (% of 10f) <sup>*5</sup>            | 14.7              | 14.2   | 14.0   | 14.2          | 13.1      |
| <b>Infection: Peritoneal dialysis (PD)</b> |  |                   |        |        |               |           |
|  |  | 2020 <sup>^</sup> | 2021   | 2022   | 2023          | 2023      |
| 10i  | Eligible PD patients (n)   | 898               | 854    | 768    | 712           | 39,886    |
| 10j  | Eligible PD patient-months (n) <sup>*C</sup>                         | 4,593             | 6,022  | 5,416  | 4,900         | 274,420   |
| 10k  | PD catheter infection rate per 100 PD patient-months                 | 2.6               | 2.6    | 2.6    | 2.5           | 2.5       |
| 10l  | P-value <sup>*6</sup> of 10k (compared to U.S. value <sup>*7</sup> ) | 0.129             | 0.128  | 0.154  | 0.170         | n/a       |

n/a = not applicable

[<sup>^</sup>, \*A - \*C] See **Appendix: Table Footnotes** on page 21.

[\*1] See *Guide, Section XIV* for detailed information regarding the summaries included in Table 10.

[\*2] Patient months with a catheter that have limited life expectancy, including under hospice care in the current reporting month, or with metastatic cancer, end stage liver disease, coma or anoxic brain injury in the past 12 months, were excluded.

[\*3] Includes patients with an autogenous arteriovenous (AV) fistula as the sole means of vascular access. SFR is calculated as an adjusted rate of AV fistula in use reported in 10c.

[\*4] Includes patients using a catheter continuously for three months or longer. Patients with other or missing access types (10c) are also counted as catheter in use in the numerator. Long-term catheter rate (10e) values in 2020 were calculated for quarter 4 only due to data limitations.

[\*5] Includes all patients with fistulae, regardless of whether or not they received their hemodialysis treatments using their fistulae.

[\*6] A p-value greater than or equal to 0.05 indicates the differences between the percent of patients with infection at the facility and national percentage is plausibly due to random change.

[\*7] Compared to U.S. value for that year: 2.56 (2020), 2.60 (2021), 2.46 (2022), and 2.45 (2023).

**TABLE 11: Comorbidities Reported on Inpatient Medicare Claims for Medicare Dialysis Patients Treated as of December 31<sup>st</sup> of Each Year<sup>\*1</sup>, 2020-2023**

| Measure Name   | This State |       |       |       | United States |
|--|------------|-------|-------|-------|---------------|
|  | 2020       | 2021  | 2022  | 2023  | 2023          |
| 11a Medicare dialysis patients on 12/31(n)           | 6,989      | 6,749 | 6,536 | 6,396 | 364,529       |
| 11b Comorbidity (% yes of 11a)                       |            |       |       |       |               |
| <b>Infections</b>                                    |            |       |       |       |               |
| AIDS/HIV positive                                    | 0.6        | 0.6   | 0.6   | 0.6   | 0.8           |
| Intravascular/implanted device-related <sup>*2</sup> | 4.3        | 4.6   | 4.6   | 4.7   | 4.9           |
| Hepatitis B  | 0.4        | 0.4   | 0.4   | 0.4   | 0.5           |
| Hepatitis other                                      | 1.7        | 1.5   | 1.5   | 1.3   | 1.5           |
| Metastatic   | 1.3        | 1.4   | 1.5   | 1.6   | 1.6           |
| Pneumonia  | 3.2        | 3.0   | 3.3   | 3.5   | 3.8           |
| Tuberculosis   | 0.2        | 0.2   | 0.2   | 0.2   | 0.3           |
| Other  | 17.6       | 17.3  | 17.6  | 17.9  | 19.1          |
| <b>Cardiovascular</b>                                |            |       |       |       |               |
| Cardiac arrest                                       | 0.9        | 0.9   | 0.8   | 0.8   | 1.0           |
| Cardiac dysrhythmia                                  | 17.4       | 18.1  | 18.2  | 18.6  | 19.9          |
| Cerebrovascular disease                              | 6.2        | 6.4   | 6.4   | 6.7   | 7.9           |
| Congestive heart failure                             | 27.8       | 28.6  | 29.2  | 29.8  | 32.2          |
| Ischemic heart disease                               | 24.1       | 24.5  | 24.6  | 24.5  | 26.9          |
| Myocardial infarction                                | 6.9        | 7.3   | 7.6   | 7.8   | 8.6           |
| Peripheral vascular disease <sup>*3</sup>            | 15.0       | 15.5  | 15.3  | 15.5  | 17.8          |
| <b>Other</b>   |            |       |       |       |               |
| Alcohol dependence                                   | 1.4        | 1.5   | 1.5   | 1.5   | 1.5           |
| Anemia   | 2.4        | 2.8   | 3.0   | 3.0   | 3.3           |
| Cancer   | 2.9        | 3.2   | 3.3   | 3.4   | 3.8           |
| Chronic obstructive pulmonary disease                | 13.7       | 13.8  | 14.1  | 14.0  | 14.9          |
| Diabetes   | 34.3       | 35.1  | 35.0  | 35.2  | 37.6          |
| Drug dependence                                      | 1.2        | 1.3   | 1.3   | 1.3   | 1.3           |
| Gastrointestinal tract bleeding                      | 2.6        | 2.7   | 2.8   | 2.8   | 3.2           |
| Hyperparathyroidism                                  | 18.4       | 19.1  | 19.9  | 20.7  | 21.8          |
| 11c Average number of comorbid conditions            | 2.0        | 2.1   | 2.1   | 2.2   | 2.3           |

n/a = not applicable.

[\*1] See *Guide, Section XV* for detailed information regarding the summaries included in Table 11. Based on patients with Medicare as primary insurer on 12/31 each year.

[\*2] This category includes bloodstream and other infections related to intravascular access and other implanted devices, not limited to dialysis access.

[\*3] Peripheral vascular disease includes venous, arterial and nonspecific peripheral vascular diseases.

**TABLE 12: Selected Summaries for Nursing Home (NH) Patients<sup>\*1</sup>, 2020-2023<sup>^</sup>**

| Measure Name                   | This State   |       |       |       | United States |        |
|--------------------------------|--|-------|-------|-------|---------------|--------|
|                                | 2020 <sup>^</sup>                                    | 2021  | 2022  | 2023  | 2023          |        |
| <b>Patient Characteristics</b> |  |       |       |       |               |        |
| 12.1a                          | Patients treated on 12/31 (n)                        | 1,054 | 1,068 | 1,055 | 1,079         | 60,499 |
| 12.1c                          | Age (% of 12.1a; sums to 100%)                       |       |       |       |               |        |
|                                | 18-64  | 35.6  | 34.9  | 33.8  | 34.0          | 32.5   |
|                                | 65+  | 64.4  | 65.1  | 66.2  | 66.0          | 67.4   |
| 12.1d                          | Female (% of 12.1a)                                  | 47.6  | 47.2  | 47.5  | 49.5          | 47.5   |
| 12.1e                          | Race (% of 12.1a; sums to 100%)                      |       |       |       |               |        |
|                                | African American                                     | 28.3  | 28.3  | 28.5  | 28.9          | 36.7   |
|                                | Asian/Pacific Islander                               | 5.8   | 5.9   | 5.9   | 7.8           | 4.3    |
|                                | Native American                                      | 3.2   | 3.4   | 3.3   | 3.6           | 1.7    |
|                                | White  | 62.6  | 62.2  | 61.4  | 59.4          | 57.0   |
|                                | Other/Unknown/Missing                                | 0.2   | 0.2   | 0.7   | 0.2           | 0.2    |
| 12.1f                          | Ethnicity (% of 12.1a; sums to 100%)                 |       |       |       |               |        |
|                                | Hispanic   | 10.2  | 10.2  | 10.1  | 10.4          | 14.6   |
|                                | Non-Hispanic   | 89.8  | 89.8  | 89.8  | 89.5          | 85.3   |
|                                | Unknown  | 0.0   | 0.0   | 0.0   | 0.1           | 0.1    |
| 12.1g                          | Cause of ESRD (% of 12.1a; sums to 100%)             |       |       |       |               |        |
|                                | Diabetes   | 58.4  | 58.3  | 55.9  | 56.4          | 52.7   |
|                                | Hypertension   | 23.0  | 23.5  | 25.2  | 23.9          | 28.5   |
|                                | Glomerulonephritis                                   | 5.3   | 5.2   | 4.8   | 5.0           | 4.4    |
|                                | Other  | 13.0  | 12.8  | 13.8  | 14.1          | 13.8   |
|                                | Unknown/Missing                                      | 0.3   | 0.2   | 0.3   | 0.5           | 0.7    |
| 12.1i                          | Years since start of ESRD (% of 12.1a; sums to 100%) |       |       |       |               |        |
|                                | < 1  | 20.7  | 22.9  | 22.4  | 20.8          | 21.5   |
|                                | 1-2  | 16.0  | 14.6  | 15.8  | 15.0          | 15.5   |
|                                | 2-3  | 12.9  | 12.7  | 11.7  | 13.1          | 12.7   |
|                                | 3-6  | 25.2  | 25.4  | 25.6  | 24.0          | 24.6   |
|                                | 6+   | 25.3  | 24.3  | 24.5  | 27.1          | 25.6   |
| 12.1k                          | Modality (% of 12.1a; sums to 100%)                  |       |       |       |               |        |
|                                | In-center hemodialysis                               | 94.8  | 94.0  | 93.6  | 92.4          | 90.7   |
|                                | Home hemodialysis                                    | 1.8   | 2.4   | 3.2   | 4.5           | 6.3    |
|                                | Continuous ambulatory peritoneal dialysis            | 0.2   | 0.2   | 0.1   | 0.3           | 0.2    |
|                                | Continuous cycling peritoneal dialysis               | 2.2   | 2.4   | 2.1   | 2.2           | 2.1    |
|                                | Other modality                                       | 0.9   | 1.0   | 0.9   | 0.7           | 0.7    |

(continued)

**TABLE 12 (continued): Selected Summaries for Nursing Home (NH) Patients <sup>\*1</sup>, 2020-2023 <sup>^</sup>**

| Measure Name   | This State  |         |         |         | United States |           |
|--|---|---------|---------|---------|---------------|-----------|
|  | 2020 <sup>^</sup>   | 2021    | 2022    | 2023    | 2023          |           |
| <b>Characteristics of New Dialysis Patients</b>                  |   |         |         |         |               |           |
| 12.2a  | Total number of patients with forms (n)                             | 409     | 447     | 416     | 417           | 23,376    |
| 12.2g  | Medical coverage (% of 12.2a; sums to 100%)                         |         |         |         |               |           |
|  | Employer group only   | 3.8     | 2.6     | 2.7     | 2.3           | 2.3       |
|  | Medicare (alone or combined w/ other insurance)                     | 77.8    | 79.9    | 83.0    | 82.7          | 83.0      |
|  | Medicaid only   | 11.5    | 11.6    | 9.8     | 10.6          | 9.9       |
|  | Other/Unknown/None  | 6.8     | 5.9     | 4.6     | 4.5           | 4.8       |
| 12.2k  | Number of incident hemodialysis patients (n)                        | 417     | 455     | 426     | 429           | 23,997    |
| 12.2l  | Access used at first outpatient dialysis (% of 12.2k; sums to 100%) |         |         |         |               |           |
|  | Arteriovenous fistula   | 8.7     | 6.2     | 7.8     | 7.5           | 6.3       |
|  | Arteriovenous graft   | 2.0     | 1.7     | 1.9     | 1.9           | 2.3       |
|  | Catheter  | 87.2    | 90.1    | 88.0    | 87.8          | 88.6      |
|  | Other/Unknown/Missing   | 2.1     | 2.1     | 2.3     | 2.7           | 2.8       |
| 12.2m  | Arteriovenous fistulae placed (% of 12.2k)                          | 19.7    | 15.6    | 16.7    | 17.1          | 14.5      |
| 12.2s  | Pre-ESRD nephrologist care (% of 12.2a; sums to 100%)               |         |         |         |               |           |
|  | No  | 22.2    | 19.4    | 18.7    | 15.0          | 16.4      |
|  | Yes, < 6 months   | 18.2    | 20.4    | 20.5    | 22.7          | 21.9      |
|  | Yes, 6-12 months  | 17.6    | 17.0    | 16.2    | 17.1          | 16.2      |
|  | Yes, > 12 months  | 25.8    | 24.9    | 24.8    | 25.3          | 19.9      |
|  | Unknown   | 16.1    | 18.3    | 19.8    | 19.9          | 25.5      |
| 12.2t  | Informed of transplant options (% of 12.2a)                         | 75.7    | 83.5    | 85.2    | 87.1          | 88.1      |
| <b>Mortality summary for all NH dialysis patients</b>            |   |         |         |         |               |           |
| 12.3a  | Patients (n)  | 1,949   | 1,973   | 1,966   | 1,999         | 136,455   |
| 12.3b  | Patient years (PY) at risk (n)                                      | 793.6   | 1,194.5 | 1,172.2 | 1,198.0       | 70,772.2  |
| 12.3c  | Deaths (n)  | 379     | 514     | 486     | 483           | 30,250    |
| 12.3d  | Expected deaths (n)   | 325.8   | 463.1   | 416.9   | 391.0         | 22,705.7  |
| 12.3c/12.3b  | Death Rate (per 100 PYs at risk)                                    | 46.7    | 40.8    | 43.6    | 38.2          | 42.7      |
| 12.3j  | Standardized Mortality Ratio (12.3c/12.3d)                          | 1.12    | 1.01    | 1.35    | 1.14          | 1.33      |
| 12.3e  | Withdrawal from dialysis prior to death (% of 12.3c)                | 32.8    | 31.2    | 32.8    | 33.5          | 26.3      |
| <b>Hospitalization summary for NH Medicare dialysis patients</b> |   |         |         |         |               |           |
| 12.4a  | Medicare dialysis patients (n)                                      | 1,756   | 1,777   | 1,768   | 1,791         | 121,369   |
| 12.4b  | Patient years (PY) at risk (n)                                      | 705.3   | 1,059.7 | 1,040.2 | 1,049.2       | 61,519.5  |
| 12.4g  | Total admissions (n)  | 2,137   | 3,060   | 2,904   | 3,075         | 185,577   |
| 12.4h  | Expected total admissions (n)                                       | 1,486.5 | 1,985.6 | 1,961.8 | 2,071.3       | 120,713.8 |
| 12.4g/12.4b  | Hospitalization Rate (per 100 PYs at risk)                          | 284.7   | 269.0   | 269.6   | 266.1         | 301.7     |
| 12.4i  | Standardized Hospitalization Ratio (12.4g/12.4h)                    | 1.44    | 1.53    | 1.59    | 1.42          | 1.54      |
|  | Diagnoses associated with hospitalization (% of 12.4a)              |         |         |         |               |           |
|  | Septicemia  | 24.8    | 22.2    | 22.2    | 25.2          | 22.3      |
|  | Acute myocardial infarction   | 11.8    | 11.6    | 11.9    | 11.5          | 11.4      |
|  | Congestive heart failure  | 46.7    | 46.1    | 47.2    | 45.9          | 44.8      |
|  | Cardiac dysrhythmia   | 34.3    | 35.3    | 34.5    | 35.7          | 31.7      |
|  | Cardiac arrest  | 3.9     | 4.3     | 3.4     | 3.2           | 3.8       |

(continued)

**TABLE 12 (continued): Selected Summaries for Nursing Home (NH) Patients<sup>\*1</sup>, 2020-2023<sup>^</sup>**

| Measure Name   | This State        |        |        |        | United States |
|--|-------------------|--------|--------|--------|---------------|
|  | 2020 <sup>^</sup> | 2021   | 2022   | 2023   | 2023          |
| <b>Comorbidities reported on Medicare claims</b>                     |                   |        |        |        |               |
| 12.11a Medicare dialysis patients on 12/31 (n)                       | 947               | 953    | 940    | 955    | 56,273        |
| 12.11b Comorbidity (% yes of 12.11a)                                 |                   |        |        |        |               |
| <b>Infections</b>  |                   |        |        |        |               |
| AIDS/HIV positive  | 0.8               | 1.3    | 0.8    | 0.7    | 1.0           |
| Intravascular/implanted device-related                               | 7.2               | 7.5    | 8.6    | 9.1    | 8.9           |
| Hepatitis B  | 0.7               | 1.0    | 0.6    | 0.6    | 0.9           |
| Hepatitis other  | 3.1               | 2.9    | 2.8    | 2.5    | 3.1           |
| Metastatic   | 5.0               | 4.4    | 4.5    | 4.0    | 4.5           |
| Pneumonia  | 8.6               | 8.9    | 8.6    | 8.9    | 10.5          |
| Tuberculosis   | 0.4               | 0.3    | 0.3    | 0.3    | 0.3           |
| Other  | 40.7              | 40.5   | 38.4   | 39.3   | 41.7          |
| <b>Cardiovascular</b>  |                   |        |        |        |               |
| Cardiac arrest   | 2.0               | 2.6    | 2.0    | 2.1    | 2.6           |
| Cardiac dysrhythmia  | 36.3              | 37.7   | 37.0   | 40.0   | 40.3          |
| Cerebrovascular disease  | 16.3              | 18.9   | 17.8   | 17.8   | 20.1          |
| Congestive heart failure   | 53.4              | 53.1   | 54.3   | 55.9   | 58.0          |
| Ischemic heart disease   | 44.7              | 45.8   | 44.1   | 45.6   | 48.1          |
| Myocardial infarction  | 13.7              | 16.6   | 14.2   | 15.3   | 16.3          |
| Peripheral vascular disease  | 33.5              | 34.8   | 33.7   | 35.1   | 37.6          |
| <b>Anemia</b>  |                   |        |        |        |               |
| 12.7b Eligible adult HD patient-months (n) <sup>*C</sup>             | 6,217             | 12,827 | 12,545 | 12,835 | 718,784       |
| 12.7d Hemoglobin (HD) < 10 g/dL (% of 12.7b)                         | 28.3              | 29.5   | 29.2   | 29.2   | 30.3          |
| 12.7e ESA prescribed (% of 12.7b)                                    | 78.3              | 77.3   | 78.0   | 79.8   | 80.0          |
| 12.7f Eligible adult PD patients (n)                                 | 45                | 82     | 80     | 82     | 4,557         |
| 12.7g Eligible adult PD patient-months (n) <sup>*C</sup>             | 168               | 476    | 452    | 473    | 26,501        |
| 12.7i Hemoglobin (PD) < 10 g/dL (% of 7g)                            | 26.2              | 26.0   | 26.8   | 28.4   | 28.3          |
| 12.7j ESA prescribed (% of 7g)                                       | 54.5              | 55.2   | 55.2   | 55.0   | 56.2          |
| <b>Dialysis Adequacy<sup>*2</sup></b>                                |                   |        |        |        |               |
| 12.8b Eligible adult HD Kt/V patient-months (n) <sup>*C</sup>        | 5,923             | 12,198 | 11,930 | 12,219 | 684,240       |
| 12.8j Kt/V (HD) < 1.2 (% of 12.8b)                                   | 2.3               | 2.5    | 2.3    | 2.1    | 2.3           |
| 12.8k Eligible adult PD Kt/V patients (n)                            | 31                | 82     | 80     | 82     | 4,557         |
| 12.8l Eligible adult PD Kt/V patient-months (n) <sup>*C</sup>        | 72                | 476    | 452    | 473    | 26,501        |
| 12.8n Kt/V (PD) < 1.7 (% of 12.8l)                                   | 9.0               | 8.7    | 8.2    | 8.8    | 8.9           |
| <b>Vascular Access<sup>*3</sup></b>                                  |                   |        |        |        |               |
| 12.10b Prevalent adult hemodialysis patient months (n) <sup>*C</sup> | 6,417             | 13,409 | 13,067 | 13,004 | 728,229       |
| 12.10c Arteriovenous fistula in use (% of 12.10b)                    | 51.5              | 49.4   | 47.6   | 48.6   | 48.1          |
| 12.10e Long-Term Catheter Rate (LTCR)                                | 22.3              | 21.9   | 22.3   | 23.3   | 23.3          |

n/a = not applicable; Kt/V: K = dialyzer clearance of urea; t = dialysis time; V = patient's total body water.

[\*1] See *Guide, Section XVI* for detailed information regarding the summaries included in Table 12.

[\*2] Kt/V summaries are supplemented with Medicare claims if missing in EQRS. HD Kt/V summaries are restricted to patients who dialyze thrice weekly. See section of *Guide* titled "*Determination of Thrice Weekly Dialysis*" for more information. PD Kt/V summaries select the most recent value collected within 4 months of the reporting month.

[\*3] Patient months with a catheter that have limited life expectancy, including under hospice care in the current reporting month, or with metastatic cancer, end stage liver disease, coma or anoxic brain injury in the past 12 months, were excluded. Other or missing access types are counted as catheter in use in the numerator. LTCR includes patients using a catheter continuously for three months or longer.

## Appendix: Table Footnotes

This appendix provides information that applies to multiple tables.

[^] CMS Extraordinary Circumstances Exceptions: Mortality (Table 3), Hospitalization (Table 4), Transplantation (Table 5), Waitlist (Table 5), Transfusion (Table 6), and PD infection (Table 10) summaries exclude data from March through June 2020 from all calculations. Readmission statistics (Table 4) are further limited to index discharges between January 1-30, 2020 and July-December 2020. Anemia Management (Table 7), Dialysis Adequacy (Table 8), Mineral Metabolism (Table 9), and Vascular Access (Table 10) summaries exclude data from January through June 2020 from all calculations.

[\*A] This value is the ratio of observed events to expected events.

[\*B] Ratios within the range 0.95 to 1.05 will not have a p-value. A p-value  $\geq 0.05$  indicates that the ratio is  $>1.05$  or  $<0.95$  plausibly due to random chance.

[\*C] A patient may be counted up to 12 times per year.

SAMPLE